ABOUT COGNIZANT
Cognizant’s Life Sciences business unit partners with biopharmaceutical and med-tech companies to develop strategies and apply solutions to healthcare challenges across the value chain. Our services and products, including the Cognizant® Shared Investigator Platform (SIP), are digitizing interactions between sponsors and investigators across every phase, helping the industry subtract time from clinical development and add it to patient lives. Headquartered in the U.S., Cognizant is ranked 194 on the Fortune 500 and is consistently listed among the most admired companies in the world. To learn more, visit cognizant.com/us/en/industries/life-sciences-technology-solutions
VIDEOS
Overcome obstacles associated with collaboration that, when left unaddressed, lead to site selection and patient enrollment issues for sponsors and operational challenges for sites.
Industry experts share their perspectives on end-to-end clinical development, essential elements of a unified clinical platform, and the benefits and challenges involved a unified clinical platform.
View this webinar to find out how the Cognizant® Shared Investigator Platform (SIP) automates the flow of documents connecting sponsor eTMF systems while enhancing site-sponsor collaboration, compounding efficiencies, and accelerating trials.
As clinical trials grow more complex, stakeholders urgently need to improve clinical trial efficiencies. Explore a solution for virtual monitoring, study oversight, and document exchange and collaboration, that enables sites, sponsors, and CROs to adapt to the new normal of conducting clinical trials virtually.
The Cognizant Shared Investigator Platform (SIP) supports a new, site-first approach for streamlining clinical trial processes. The industry’s first single-instance, multi-tenant SaaS solution, Cognizant SIP provides investigators and sponsors with a single technology platform from which they can collaborate and share documents, and harmonize workflows across the clinical trial lifecycle.
Discover how 7 of the top 15 global biopharmaceutical companies came together on a single clinical technology platform and operated through common workflows and common trial documents.
Cognizant Shared Investigator Platform (SIP) is a multi-sponsor collaborative solution for clinical trial site selection, start-up communications, and management. The open design of Cognizant SIP simplifies and accelerates clinical trials by eliminating redundant work for sponsors and clinical sites. This can lead to improved operating efficiencies, reduced costs of building and maintaining in-house technology, quicker study start up and more time spent with patients.
Seven of the top fifteen global biopharmaceutical companies are on a single clinical technology platform, leveraging one environment, operating via common workflows, documents and training.
CONTACT INFORMATION
Cognizant Technology Solutions
Glenpointe Centre West 500 Frank W Burr Blvd
Teaneck, NJ 07666
UNITED STATES
Phone: +1 201-310-2499
Contact: Kavitha Lokesh
BROCHURES
- Shared Investigator Platform Simplifies Collaboration Between Sites & Sponsors
- Transform Clinical Trials With Cognizant SIP: Efficient, Collaborative, Virtual
- The Cognizant® Shared Investigator Platform (SIP) Document Exchange Module
- Optimize Your Safety Notification Process With The Cognizant SIP Safety Exchange Module
- Seamlessly Connect Sponsor eTMF Systems And The Florence eISF
- Cognizant® Shared Investigator Platform Video Meetings
- Modernize Operations To Support A New Way Forward For Clinical Trials With Cognizant® SIP
FEATURED ARTICLES
-
![gettyimages1350791957]( "Streamlined Clinical Trial Feasibility: Unlocking The Site-Sponsor Relationship")
Determining the feasibility of a site for clinical research is a critical component of the entire trial process. Discover how automation and standardization can improve the site-sponsor journey.
-
![DNA GettyImages-513751816]( "Adoption Remains Strong For Cognizant® Shared Investigator Platform")
Cognizant’s Life Sciences business unit partners with biopharmaceutical and med-tech companies to develop strategies and apply solutions to healthcare challenges across the value chain.
-
![GettyImages-547418608-lab-team-collaboration-planning]( "Harmonizing Site & Sponsor Platforms To Accelerate Startup & Monitoring")
Now more than ever, stakeholders need harmony among their disparate systems — and that starts with the right organizational mindset: a culture of connectivity.
-
![clinical staff (002)]( "Clinical Trials Separate The Signal From The Noise")
Avi Kulkarni, Senior Vice President, Research & Development, at Cognizant, speaks about the trajectory and growth of the Shared Investigator Platform, the history and impact of biomarkers in clinical trial conducts, and the personal insights from his 30-year career.
-
![Clinical Supply Forecasting And Planning]( "Roche Cuts Feasibility Process By 36%")
Discover the solutions to how an industry pioneer and veteran biotech struggled with complexity and consistency when it came to its approach to clinical trial feasibility.
-
![iStock-1251299015-lab-scientist-research-microscope]( "Growth Remains Strong For Shared Investigator Platform In 2021")
Cognizant SIP has maintained its growth momentum in 2021 as research sites have continued their adoption of the platform at a steady pace.
-
![cognizantebook]( "SIP Support For The “New Normal” In The COVID-19 Crisis")
In the “New Normal,” Sponsors and sites collaborate remotely throughout the trial lifecycle by leveraging a solution that streamlines trial set-up and execution, leading to improved site experiences and faster time-to-market.
-
![iStock-1196710425-450]( "It’ll Take New Tools And Partnerships To Fast-Track Clinical Trials For A COVID-19 R<sub>X</sub>")
The industry needs new tools, technologies, and partnerships to collaborate virtually on clinical trials for COVID-19 treatments.
-
![Coronavirus vaccine, syringe COVID 19]( "Agile Drug Development Required In A New Age Of Urgency")
Why it’s time to reconsider the current drug development paradigm. Complementing traditional RCTs with accelerated RWE studies and real-time clinical analysis provides true benefits.
